期刊文献+

人甲状旁腺素N-端34肽基因的合成、克隆和融合表达

Synthesis,Cloning and Fusion Expression of Gene Encoding 34 Peptides at N-termi nus of Human Parathyroid Hormone
下载PDF
导出
摘要 目的构建重组人甲状旁腺素N-端34(PTH34)肽的大肠杆菌融合表达菌株,并对其表达产物进行检测。方法选用大肠杆菌偏爱密码子,设计优化的人甲状旁腺素N-端34肽基因序列,通过6个DNA片段分段合成、片段连接、PCR扩增,经TA克隆到pMD18载体中,经测序验证,构建GST融合表达载体。结果经SDS-PAGE检测PTH(1-34)肽与GST蛋白的融合表达,经Westernblot分析具有免疫活性,通过GST亲和层析和Xa因子酶切,利用小分子蛋白电泳可检测到PTH(1-34)肽。结论已获得了能表达GST-PTH(1-34)融合蛋白的菌株。表达产物具有免疫活性,且能被Xa因子消化得到PTH(1-34)肽。 Objective To construct a recombinant E.coli strain expressing the 34 peptides at N-te rminus of human parathyroid hormone (PTH34) and identify the expressed product. Methods Design an optimal gene sequence encoding the PTH34 using E.coli-preferred c odons and synthesize 6 DNA fragments separately.Link the fragments with ligase,a mplify by PCR and clone into pMD18 vector by T-A cloning.Identify the recombina nt plasmid by DNA sequencing and transform to E.coli for GST fusion expressi on. Results The fusion expression of PTH(1-34) and GST protein was proved by SDS-PAGE.West ern blot showed immunological activity of expressed product.After the fusion pro tein was purified by GTST affinity chromatography and digested with Xa factor,PT H(1-34) was revealed by small molecule protein electrophoresis. Conclusion A recombinant E.coli strain expressing GST-PTH(1-34) was successfully cons tructed.The expressed product showed immunological activity and might be digeste d into PTH(1-34) with Xa factor.
出处 《中国生物制品学杂志》 CAS CSCD 2005年第4期284-287,共4页 Chinese Journal of Biologicals
关键词 甲状旁腺素 N-端34肽 基因合成 基因克隆 融合表达 免疫活性 Parathyroid hormone Gene synthesis Fusion expression
  • 相关文献

参考文献10

  • 1Jiang Y, Zhao JJ, Mitlak BH, et al, Recombinant human parathyroid hormone (1-34) [ teriparatide ] improves both cortical and cancellous bone structure. J Bone Miner Res,2003,18(11): 1932-1941.
  • 2张艳,李成文,赵丹慧.人甲状旁腺激素结构与功能研究进展[J].生物技术通讯,2001,12(3). 被引量:6
  • 3Shimizu M, Potts JT, Gardella TJ.Minimization of parathyroid hormone.Novel amino-terminal parathyroid hormone fragments with enhanced potency in activating the type-1 parathyroid hormone receptor. J Biol Chem,2000,275(29) :21836-21843.
  • 4王洪复,金慰芳,高建军,顾淑珠,周轶,孙爱龙,胡菲,沈洁,张顺昌.重组人甲状旁腺激素_(1-34)对去卵巢大鼠骨质疏松的治疗作用[J].中国医学科学院学报,2003,25(3):275-279. 被引量:25
  • 5Sung WL, Zahab DM, Barbier JR, et al. Specific degenerate codons enhanced selective expression of human parathyroid hormone in Escherichia coli. J Biol Chem, 1991,266(5) :2831-2835.
  • 6Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide recombinant human parathyroid hormone (1-34) on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res, 2003,18(3):539-543.
  • 7Marx UC, Adermann K, Bayer P, et al. Structure-activity relation of NH2-terminal human parathyroid hormone fragments. J Biol Chem,1998,273(8) :4308-4316.
  • 8Jin L, Briggs SL, Chandrasekhar S, et al. Crystal structure of human parathyroid hormone 1-34 at 0.9-A resolution. J Biol Chem, 2000,275(35): 27238-27244.
  • 9Takasu H, Gardella TJ, Luck MD, et al. Amino-terminal modifications of human parathyroid hormone (PTH) selectively alter phospholipase C signaling via the type 1 PTH receptor: implications for design of signalspecific PTH ligands. Biochemistry, 1999,38(41 ): 13453-13460.
  • 10石继红,赵永同,张英起,颜真,韩苇,王俊楼.应用SDS-PAGE显示小分子多肽技术的探讨[J].生物工程进展,2001,21(1):38-41. 被引量:42

二级参考文献46

  • 1Sambrook j Fritsch EF.分子克隆实验指南(第2版)[M].北京:科学出版社,1992..
  • 2Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in Primary hyperparathyroidism. J Bone Miner Res,1989, 4:281-291.
  • 3Rubin Mr, Cosman F, Lindsay IL et al. The anabolic effects of parathyroid hormone. Osteoporos Int, 2002, 13:267-277.
  • 4Ejersed C, Andeassen TF, Hauge EM, et al. Parathyroid bormone(1-34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone, 1995, 17(6):507-511.
  • 5Sato M, Vahle J, Schmidt A, et al. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology, 2002, 143:3230-3242.
  • 6Okimoto N, Tsurukami H, Okazaki Y, et al. Effects of a weekly injection of human parathyroid hormone(1-34) and withdrawal on bone mass, stxength, and tumover in mature ovariectomized rats. Bone, 1998, 22:523-531.
  • 7Brommage R, Hotchkiss CE, Lces CJ, et al. Daily treatment with human recombinant parathyroid hormone(1-34) LY333334,for l year increases bone mass in ovariectomized monkeys.J Clin Endocrinol Metab, 1999. 84(10):3757-3763.
  • 8Sato M, Weatmore M, Clendenon J, et al. Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumber vertebrate of ovariectomized cynomolgus macaques. Osteoporm lnt, 2000, 11(10):871-880.
  • 9Ma YL, Cain RI, Helladay DL, et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology,2001, 142:4047-4054.
  • 10Locklin RM, Khosla S, Riggs BL. Mechanism of biphasic and catabolic effects of parathyroid hormone(PTH) on bone cells. Bone, 2001, 28 (Suppl):580.

共引文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部